ニュースProgenity, Inc. is developing PGN-600 program.Progenity is developing the PGN-600 program, which consists of oral liquid formulation of tofacitinib delivered to the colon via the DDS capsule, for the treatment of ulcerative colitis.
ニュースProgenity, Inc. sold assets to Nwpathology in the amount of $10.9M on Dec 20th '21.Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced it has successfully closed the business divestiture of its affiliate Avero Diagnostics through an asset sale to Northwest Pathology.
ニュースProgenity, Inc. launched patent related to single-molecule detection platform on Dec 2nd '21.Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics, today announced a new patent related to its single-molecule detection platform under development.
